Scarica l'app Stockscreener
4.10
9.89%
-0.45
Dopo l'orario di chiusura:
4.10
Precedente Chiudi:
$4.55
Aprire:
$4.53
Volume 24 ore:
104.98K
Relative Volume:
0.47
Capitalizzazione di mercato:
$144.84M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-2.0724
EPS:
-1.9784
Flusso di cassa netto:
-
1 W Prestazione:
+1.74%
1M Prestazione:
+58.91%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.07
$4.5775
Intervallo di 1 settimana:
$3.92
$4.75
Portata 52W:
$2.34
$8.79
Anteris Technologies Global Corp Stock (AVR) Company Profile
Nome
Anteris Technologies Global Corp
Settore
Industria
Telefono
651-493-0606
Indirizzo
860 BLUE GENTIAN ROAD, EAGAN
Confronta AVR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
4.10 | 144.84M | 0 | 0 | 0 | -1.9784 |
|
ISRG
Intuitive Surgical Inc
|
565.94 | 192.17B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
171.02 | 47.90B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.24 | 47.53B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
246.99 | 35.88B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
80.47 | 16.25B | 3.93B | 415.40M | 384.70M | 2.06 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-08 | Iniziato | Lake Street | Buy |
| 2025-01-07 | Iniziato | Barclays | Overweight |
| 2025-01-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
Anteris Technologies Global Corp Borsa (AVR) Ultime notizie
Anteris Technologies advances toward PARADIGM trial after key regulatory and clinical milestones - Proactive financial news
Anteris scales for pivotal PARADIGM Trial, plunging R&D investment into clinical activities - Proactive financial news
The morning catch up: ASX to extend gains as global optimism lifts markets - Proactive financial news
Anteris Technologies Advances Clinical Trial Efforts with DurAVR® THV - TipRanks
Anteris Technologies Reports Q1 2025 Results and Strategic Fund Allocation - TipRanks
Anteris Announces Results for the First Quarter of 2025 - The Manila Times
Anteris Technologies Files Amendment to Annual Report - TipRanks
Anteris Technologies Announces Cessation of Certain Securities - TipRanks
Anteris Technologies Global Corp. (AVR) Receives a Buy from Lake Street - The Globe and Mail
ASX Runners of the Week: Redstone Resources, Anteris & Jindalee Lithium - businessnews.com.au
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Anteris stock Overweight with $9 target - Investing.com
Anteris Technologies Announces Cessation of Securities - TipRanks
Anteris Technologies Announces New Securities Quotation - TipRanks
NanoVibronix (NASDAQ:NAOV) & Anteris Technologies Global (NASDAQ:AVR) Head to Head Review - Defense World
Anteris Technologies Reports March 2025 CDI Adjustments - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV By Investing.com - Investing.com Canada
Anteris reports over 100 patients treated with new heart valve By Investing.com - Investing.com South Africa
Anteris Technologies Hits Milestone with DurAVR® Heart Valve Treatment - Zenopa
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewswire
Anteris reports over 100 patients treated with new heart valve - Investing.com
Anteris Technologies announces 100 patients treated with DurAVR THV - TipRanks
Anteris Technologies Achieves Key Milestone in Cardiac Care - TipRanks
Anteris Technologies Marks Clinical Milestone with DurAVR® THV - Investing.com
Anteris Technologies Achieves Milestone with DurAVR® Heart Valve - TipRanks
Anteris Technologies marks clinical milestone with more than 100 patients treated using flagship DurAVR® THV - Proactive financial news
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq - MSN
Head to Head Survey: Anteris Technologies Global (NASDAQ:AVR) & United Health Products (OTCMKTS:UEEC) - Defense World
Anteris Technologies reports one-year patient outcomes for DurAVR THV - TipRanks
Anteris shares rise on positive valve trial results By Investing.com - Investing.com Canada
Anteris Reports One-Year Patient Outcomes for DurAVR® THV - The Manila Times
Anteris shares rise on positive valve trial results - Investing.com India
Anteris Technologies Unveils Positive DurAVR® Patient Outcomes - TipRanks
Anteris Technologies delivers strong one-year results for DurAVR® Transcatheter Heart Valve - Proactive financial news
Analyzing Anteris Technologies Global (NASDAQ:AVR) & CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Anteris Technologies Global (NASDAQ:AVR) Stock Price Down 6.2% – What’s Next? - Defense World
Anteris Technologies: Advancing Toward FDA Approval with Positive Buy Rating - TipRanks
Anteris Technologies reports annual financial results By Investing.com - Investing.com South Africa
Anteris Technologies reports annual financial results - Investing.com India
Anteris Technologies 2024 financials strong following Nasdaq debut, with plans for heart valve pivotal trial this year - Proactive financial news
Anteris Technologies: A Trailblazing Year of Innovation and Expansion - Kondor EXP
The morning catch up: ASX to reverse losses despite war of words over tariffs - Proactive financial news
Anteris Technologies Global Corp Azioni (AVR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anteris Technologies Global Corp Azioni (AVR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Paterson Wayne | Chief Executive Officer |
Mar 05 '25 |
Option Exercise |
7.13 |
233,000 |
1,661,290 |
233,000 |
| Denaro Stephen | Director |
Mar 11 '25 |
Option Exercise |
7.13 |
16,500 |
117,645 |
23,722 |
3.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):